Vera Therapeutics (NASDAQ:VERA) Stock Bumped Up to “Sell” by Wall Street Zen

Vera Therapeutics (NASDAQ:VERA) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.

VERA has been the topic of a number of other research reports. TD Cowen restated a “buy” rating on shares of Vera Therapeutics in a research report on Tuesday, September 15th. Wedbush reduced their target price on Vera Therapeutics from $34.00 to $29.00 and set a “neutral” rating for the company in a report on Friday. Guggenheim reduced their price objective on Vera Therapeutics from $76.00 to $66.00 and set a “buy” rating on the stock in a research report on Friday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vera Therapeutics in a research note on Friday, October 23rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Vera Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $74.93.

Vera Therapeutics Stock Down 1.2%

NASDAQ VERA opened at $29.78 on Friday. Vera Therapeutics has a twelve month low of $23.86 and a twelve month high of $56.05. The stock has a market cap of $2.15 billion, a PE ratio of -5.05 and a beta of 1.07. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.92 and a current ratio of 10.92. The firm has a 50-day simple moving average of $31.60 and a 200 day simple moving average of $36.68.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($1.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.62) by $0.32. The business had revenue of $10.28 million for the quarter, compared to analysts’ expectations of $3.42 million. On average, research analysts forecast that Vera Therapeutics will post -6.45 EPS for the current year.

Insider Buying and Selling

In other news, CEO Marshall Fordyce sold 18,500 shares of the business’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $37.00, for a total transaction of $684,500.00. Following the completion of the sale, the chief executive officer directly owned 235,244 shares of the company’s stock, valued at $8,704,028. The trade was a 7.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 15.90% of the company’s stock.

Institutional Investors Weigh In On Vera Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Pictet Asset Management Holding SA increased its position in Vera Therapeutics by 47.2% during the 3rd quarter. Pictet Asset Management Holding SA now owns 1,839,245 shares of the company’s stock worth $59,397,000 after purchasing an additional 589,831 shares in the last quarter. Candriam S.C.A. lifted its stake in Vera Therapeutics by 21.5% in the 3rd quarter. Candriam S.C.A. now owns 568,560 shares of the company’s stock valued at $18,426,000 after purchasing an additional 100,461 shares during the last quarter. Braidwell LP lifted its holdings in Vera Therapeutics by 7.8% during the 2nd quarter. Braidwell LP now owns 564,724 shares of the company’s stock worth $24,232,000 after buying an additional 40,900 shares during the period. Renaissance Technologies LLC increased its position in shares of Vera Therapeutics by 136.5% during the first quarter. Renaissance Technologies LLC now owns 457,300 shares of the company’s stock valued at $18,397,000 after acquiring an additional 263,900 shares during the last quarter. Finally, Orbimed Advisors LLC grew its position in Vera Therapeutics by 4.6% during the first quarter. Orbimed Advisors LLC now owns 369,596 shares of the company’s stock valued at $14,869,000 after acquiring an additional 16,096 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Vera Therapeutics

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: For Q3 2026, Vera reported a loss of $1.30 per share, narrower than the $1.62 consensus loss, and revenue of $10.28 million versus estimates of $3.42 million. The earnings beats are supportive, although the company remained loss-making. Quarterly earnings report
• Positive Sentiment: HC Wainwright cut its price target to $75 from $90 but maintained a Buy rating. Its revised target still implies substantial upside from the cited $29.79 share price, which may offer support to investors. HC Wainwright rating update
• Neutral Sentiment: Vera granted stock options covering 14,900 shares and restricted stock units covering 7,450 shares to three new employees. The awards are a routine hiring incentive, with a small potential dilution effect. Inducement grants announcement
• Negative Sentiment: A valuation-focused article argues VERA may be above fair value after a 148% run, raising the risk that investors take profits or demand stronger progress to justify the share price. Valuation analysis
• Negative Sentiment: Although HC Wainwright remains bullish, its $15 reduction in the target reflects a more cautious view than before and may temper optimism. HC Wainwright rating update

About Vera Therapeutics

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immunological diseases. The company’s research is centered on therapies that target the underlying causes of autoimmune conditions rather than primarily addressing their symptoms.

Vera’s lead product candidate is atacicept, a biologic designed to inhibit the B-cell survival factors BLyS and APRIL. The company has been evaluating atacicept in IgA nephropathy, an autoimmune kidney disease that can lead to progressive loss of kidney function, and has also investigated its potential in other immune-mediated diseases.